Castle Biosciences, Inc. (CSTL)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 03:15PM EDT. Market open.
| Previous close | 20.11 |
| Open | 19.95 |
| Bid | 19.52 x 1000 |
| Ask | 19.60 x 900 |
| Day's range | 19.28 - 20.64 |
| 52-week range | 17.01 - 78.92 |
| Volume | |
| Avg. volume | 339,190 |
| Market cap | 516.815M |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.04 |
| Earnings date | 08 Aug 2022 - 12 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 48.29 |
- Business Wire
TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia
FRIENDSWOOD, Texas, May 24, 2022--Castle announced new data showing that its TissueCypher® test outperformed standard of care in predicting progression in Barrett’s esophagus patients.
- Business Wire
Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer
NEW YORK & FRIENDSWOOD, Texas, May 20, 2022--Research to Prevent Blindness and Castle are partnering to increase opportunities for medical students to gain research experiences in ocular cancer.
- Business Wire
Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC
FRIENDSWOOD, Texas, May 19, 2022--New data presented at ACMS confirms independent risk-stratification performance of Castle's DecisionDx®-SCC test.
© 2022 Yahoo. All rights reserved.
